Tags Posts tagged with "Emblem"


0 4223

Before the market closed yesterday, shares of Emblem Corp. (EMC.V) (EMMBF) were halted at the request of the company.

The halt was due to the announcement of an engagement letter with PI Financial on behalf of a syndicate of underwriters that includes Canaccord Genuity and GMP Securities.

The syndicate agreed to purchase 2,754,821 special warrants at a price of $3.63 for $10 million in aggregate gross proceeds and the offering is expected to close on January 26th. Emblem also granted the underwriters an option to purchase up to an additional 15% of special warrants.

Terms of the Raise

The holders will receive one unit for each special warrant held. Each unit is comprised of one common share and one-half of one common share purchase warrant. Each warrant allows the holder to purchase one share at $4.75 for a period of 36 months from the closing date.

The warrants are subject to an accelerated expiry date if the volume weighted average trading price is greater than or equal to $7 over a period of 10 consecutive trading days.

Use of Proceeds

Emblem intends to use the proceeds to fund the planned expansion of its facility and for general corporate purposes. The company plans to build a 2,500 square-foot extraction and formulation development laboratory on its existing property.

Emblem also hired a team of scientists to focus exclusively on the development and manufacture of advanced dosage forms of cannabinoid medication. With this capital, Emblem will be able to bring several pharmaceutical formulations to market in a much shorter period of time.

In July, Emblem purchased state-of-the-art oil extraction equipment and the company has invested more than $1 million into this division. Demand for cannabis oils, especially high CBD oil, continues to increase and this is an area we expect to see Emblem capitalize on after Health Canada issued the company a cannabis oils license in December.

Increased Institutional Focus

Since inception, Emblem has been dedicated to its existing shareholder base and 92% of all funds raised have been from retail investors.

Emblem was one of the most highly anticipated and most successful initial public offerings in 2016 and institutional investors have taken notice of this. These firms want to help Emblem advance its business plan, specifically in regard to its pharmaceutical division.

Emblem’s pharmaceutical division is led by one of the top pharmaceutical executives in the world, John Stewart. Stewart has over 30 years experience developing and commercializing pharmaceutical products. He has launched 11 new products, including OxyContin, and was the worldwide President and CEO of Purdue Pharma, the largest privately held pharmaceutical company in the world.

In the second quarter of 2017, Stewart plans to lead the launch of cannabinoid-based medications in customary pharmaceutical dosage forms such as liquids, gel caps, oral sprays, and inhalers.

Interested Investors Need to Act Fast

Although this offering is primarily for financial institutions and will most likely be significantly over-subscribed, Emblem has made a limited number of units available to retail investors through a Presidents list.

If you are interested in participating in this offering, please contact us as soon as possible and we will connect you to the Emblem team or email dannybrody@emblemcorp.com

Join Technical420 and Capitalize on the Rapidly Growing Cannabis Industry…

Important Investor Disclosures

Disclosure. Compensated Affiliate. This report was authored by and is property of StoneBridge Partners LLC. All information and data relied upon in drafting this report is publicly available. The author believes and considers its sources to be reliable, but does not guarantee the accuracy or completeness of any information contained in this report. Any and all information, data, analyses and opinions are provided for informational purposes only and is not intended, in any manner, as investment advice. Any projections or other information generated by StoneBridge Partners LLC regarding the likelihood of various investment outcomes are hypothetical in nature, do not reflect actual investment results, and are not guarantees of future results. None of the material contained in this report is intended as a solution or offer to sell or purchase a specific stock or any other investment. This report is not directed to, or intended for distribution or use by, any person or entity that is a citizen, resident or located in any municipality, state, country or other jurisdiction where the distribution, publication, availability, or use of this report is contrary to any governing law or regulation. The securities discussed in this report may not be eligible for purchase and/or sale in certain jurisdictions or by particular individuals. It is important that you check any and all governing laws and/or regulations that may be applicable in your jurisdiction. Investing in securities of issuers organized outside of the United States, including ADRs, entail certain risks. The securities of non-United States issuers may not be registered with, nor be subject to the reporting requirements of the United States Securities and Exchange Commission. Please contact a Financial Advisor for professional advice regarding any and all securities investments. This report is intended for informational purposes only. StoneBridge Partners LLC’s officers, directors, employees, affiliates, or subsidiaries may have positions in securities covered by StoneBridge Partners LLC. StoneBridge Partners LLC receives compensation from the company and/or has a position in the securities mentioned in this report

Authored by: Michael Berger

To read more articles like this click the link “here

0 2042

Emblem Corp.’s chairman Gordon Fox has provided an update to shareholders, reviewing its accomplishments to date and its plans going forward in 2017.

Welcome to the Emblem story! We feel we have built an exceptional management team to implement our unique three pronged approach to the industry. Our production division is committed to cultivating the highest quality product possible. Our healthcare division, GrowWise Health, is designed to address the challenges that patients are confronting as they attempt to access the ACMPR system. Our pharmaceutical division is pioneering the next generation of Canadian medical cannabis: medication made available in standard pharmaceutical dosage formats.

We believe that the Emblem senior management team (myself, Gordon Fox, and my partners Harvey Shapiro, Maxim Zavet, and John Stewart) are uniquely qualified to carry out this demanding business plan. Our mission is to pursue a patient-centric model with a relentless commitment to quality and a dedication to innovation.

Today, Emblem is fully licensed and actively registering patients. Our facility in Paris, ON was designed and built to produce elite quality dried flower. From inception we have been successful in raising over $42 million dollars of capital and we currently enjoy a cash position of $27 million as we expand our production capacity for medical offerings and prepare for the onset of the recreational market.

Our facility currently operates with two flowering rooms, one vegetation room, one mothering room and one propagation room, supported by trimming and drying facilities, fulfillment, administration and a 625kg vault. We will commission three new growing rooms in March and a 4th in June. We’re currently growing a total of 12 strains, with a variety of CBD and THC strains, (indica, sativa & hybrids). We have an excellent cultivation plan and a superb growing team to carry it out. Our growers are passionate and experienced. Management’s mission is to provide our growers with the ideal growing environment to produce the highest quality offerings for both the medical and anticipated recreational market.

Recent trends in the medical cannabis market are encouraging. The registered patient base for the industry appears to be growing at the extraordinary rate of about 10% per month. However, the number of physicians prescribing medical cannabis still appears to be below 5% of the total. While patient numbers may be increasing, they continue to confront difficulty accessing the system.

GrowWise is committed to meeting this challenge. GrowWise continues to expand its clinic network and we expect it to be serving a significant patient base by the end of 2017.

We continue to believe that medical cannabis in Canada will experience fundamental change in the coming years. We expect the number of authorizations filled in dried flower format to reduce materially over time and be replaced by authorizations for cannabis medication in standard pharmaceutical dosage formats. We are committed to be in the vanguard of this developing pharmaceutical field. We expect that the market for cannabinoid based pharmaceutical formulations to be significant. Emblem is committed to deploying the laboratory facilities and building the scientific team capable of developing a range of formulations to reach these markets.

We were gratified by a number of elements of the recent report of the Canadian Taskforce on Cannabis Legislation. The report confirms the strong recommendation that the current licensing and regulatory regime continue for recreational marihuana. A recommendation that attracted less attention but that is extremely important is the recommendation that the current e-commerce model be allowed to continue into the recreational regime. This will allow high quality producers such as Emblem maximum flexibility in reaching a Canada-wide market and optimizing margins.

We continue to perceive that the recreational market will evolve into a distinct “table wine” market and “fine wine” market. Emblem will be focusing on the upper echelon of the recreational market where we perceive that margins will be the most attractive. To pursue this objective Emblem will be deploying significant capital for the construction of the highest possible “closed box” horticultural environment capable of producing the highest quality product, at scale. We have plans and funding in place to build and commission capacity to 12,000 kgs annually for the arrival of recreational cannabis. We have additional longer-term plans to expand production to over 21,000 kgs annually.

We believe that we have a unique and well considered business plan. More important, we believe that we have the senior management team to drive it home.

We have enjoyed unwavering support from our shareholders for which we are eternally grateful. We thank you for being a part of our journey into the public markets, and look forward to delivering on our business plan.

0 3330
marijuana stocks

Activity within the Canadian cannabis industry has picked up over the last two weeks and we believe this is just beginning as the month of December has been highlighted by increased M&A activity, company funding agreements and new investment opportunities.

One of the most highly anticipated initial public offerings (IPO) will take place today as Emblem Corp is set to commence trading on the TSX Venture Exchange this morning under the symbol EMC.V.

Emblem is a licensed medical cannabis producer in Canada uniquely positioned within the rapidly growing medical and recreational cannabis industry.

An Attractive Cannabis and Biotech Investment

We are favorable on Emblem for the following reasons: 1) The company operates three distinct divisions which can create value for each other, 2) It recently completed a capital raise that was oversubscribed and the company has seen remarkably high interest from the marketplace, 3) Its Emblem Cannabis division started selling medical cannabis in August and we expect to see continued growth on a month-over-month basis, 4) It is led by a management team that has a proven track record of building successful multi-billion dollar companies, and 5) Its current valuation is attractive as we expect to see incremental growth on a year-over-year basis.

Emblem’s pharmaceutical efforts are led by President John Stewart who will lead the launch of cannabinoid-based medications in customary pharmaceutical dosage forms such as liquids, gel caps, oral sprays, and inhalers. Stewart has launched 11 new products, including OxyContin and was previously the CEO of Purdue Pharma, the largest privately held pharmaceutical company in the world.

By using a more natural cannabis extract, Stewart is trying to create safe standardized dosage medication in pill form. The development of a product like this would allow Emblem to compete in the global pain and sleep market, the largest pharmaceutical markets in the world.

An Attractive Management Team and Valuation

Emblem is led by its founders and a management team with a proven track record of success. Since inception, management has invested over $6 million and executed on its plan to build a state-of-the-art facility that produces world class products.

The company’s flawless execution and excellent capital structure (includes over 1,000 shareholders) makes Emblem incredibly attractive to the capital markets.

Its pre-IPO valuation is $63 million ($90 million on a fully diluted basis) which is very attractive as it is significantly lower than other licensed medical cannabis producers in Canada.

We expect Emblem to see rapid growth on account of its unique three-pronged approach: dedicated to the production of premium quality cannabis, patient and physician education creating easy access and a pharmaceutical approach that is second to none.

Canadian Broker-Dealer Releases Report on Emblem

PI Financial released a report on Emblem that provides insight to the business. The analyst, Jason Zandberg, issued the company a Buy rating and a $3.25 price target within the first 12 months.

Zandberg said, “Emblem has a number of things in its favor, including a strong management team, a state-of-the-art facility in Ontario, a solid patient onboarding strategy, and a pharmacy background, which he thinks will prove to be important because he expects pharmacies will ultimately act as distribution points for marijuana.”


Authored By: Michael Berger

Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Marijuana Stocks, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
Ad Placements